[go: up one dir, main page]

EA201171367A1 - Винилиндазолильные соединения - Google Patents

Винилиндазолильные соединения

Info

Publication number
EA201171367A1
EA201171367A1 EA201171367A EA201171367A EA201171367A1 EA 201171367 A1 EA201171367 A1 EA 201171367A1 EA 201171367 A EA201171367 A EA 201171367A EA 201171367 A EA201171367 A EA 201171367A EA 201171367 A1 EA201171367 A1 EA 201171367A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
vinylindasolyl
vinylindazolyl
cancer
treatment
Prior art date
Application number
EA201171367A
Other languages
English (en)
Other versions
EA018149B1 (ru
Inventor
Даохун Чэнь
Хун-Юй Ли
Гэньши Чжао
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201171367A1 publication Critical patent/EA201171367A1/ru
Publication of EA018149B1 publication Critical patent/EA018149B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Согласно настоящему изобретению предложены винилиндазолильные соединения, подходящие для применения для лечения рака.
EA201171367A 2009-05-07 2010-05-04 Винилиндазолильные соединения EA018149B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17629009P 2009-05-07 2009-05-07
US30141610P 2010-02-04 2010-02-04
PCT/US2010/033487 WO2010129509A1 (en) 2009-05-07 2010-05-04 Vinyl indazolyl compounds

Publications (2)

Publication Number Publication Date
EA201171367A1 true EA201171367A1 (ru) 2012-04-30
EA018149B1 EA018149B1 (ru) 2013-05-30

Family

ID=42238704

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171367A EA018149B1 (ru) 2009-05-07 2010-05-04 Винилиндазолильные соединения

Country Status (34)

Country Link
US (1) US8268869B2 (ru)
EP (1) EP2427449B1 (ru)
JP (1) JP5555314B2 (ru)
KR (1) KR101373910B1 (ru)
CN (1) CN102421769B (ru)
AR (1) AR078411A1 (ru)
AU (1) AU2010246114B2 (ru)
BR (1) BRPI1013748A2 (ru)
CA (1) CA2760535C (ru)
CL (1) CL2011002781A1 (ru)
CO (1) CO6450624A2 (ru)
CR (1) CR20110580A (ru)
DK (1) DK2427449T3 (ru)
EA (1) EA018149B1 (ru)
EC (1) ECSP11011441A (ru)
ES (1) ES2408117T3 (ru)
HN (1) HN2011002809A (ru)
HR (1) HRP20130323T1 (ru)
IL (1) IL216004A (ru)
JO (1) JO2860B1 (ru)
MA (1) MA33244B1 (ru)
ME (1) ME01462B (ru)
MX (1) MX2011011342A (ru)
MY (1) MY160390A (ru)
NZ (1) NZ595553A (ru)
PE (2) PE20160124A1 (ru)
PL (1) PL2427449T3 (ru)
PT (1) PT2427449E (ru)
RS (1) RS52795B (ru)
SG (1) SG175909A1 (ru)
SI (1) SI2427449T1 (ru)
TW (1) TWI382982B (ru)
UA (1) UA104756C2 (ru)
WO (1) WO2010129509A1 (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PT2824181T (pt) 2012-03-08 2018-12-20 Astellas Pharma Inc Novo produto de fusão de fgfr3
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA2907152A1 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
CN103819396B (zh) * 2014-02-26 2016-06-15 四川大学 一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016105517A1 (en) 2014-12-23 2016-06-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
CN105906621A (zh) * 2015-04-06 2016-08-31 四川百利药业有限责任公司 用作fgfr抑制剂的乙醇类化合物
WO2016187767A1 (en) * 2015-05-25 2016-12-01 Hutchison Medipharma Limited Pharmaceutical compositions and use thereof
CN107922349B (zh) * 2015-08-07 2021-05-07 哈尔滨珍宝制药有限公司 作为fgfr和vegfr抑制剂的乙烯基化合物
JP6549311B2 (ja) 2015-08-20 2019-07-24 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． インドール誘導体、その調製方法および医薬におけるその使用
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4056558A4 (en) * 2019-11-06 2023-12-27 Jinan University INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USES THEREOF
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
WO2021138391A1 (en) * 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2022033472A1 (zh) * 2020-08-11 2022-02-17 河南迈英诺医药科技有限公司 Fgfr抑制剂化合物及其用途
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CN116554148B (zh) * 2022-12-13 2025-01-28 药康众拓(北京)医药科技有限公司 一种乙烯基吲唑类氘代fgfr抑制剂药物及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
AP1666A (en) 2000-09-11 2006-09-29 Chiron Corp Quinolinone derivatives as tyrosine kinase inhibitors.
JP4383870B2 (ja) * 2001-10-17 2009-12-16 協和発酵キリン株式会社 線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
IL164209A0 (en) * 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
DE10342503A1 (de) * 2003-09-12 2005-04-14 Merck Patent Gmbh Benzyl-Benzimidazolylderivate
JP4093588B2 (ja) 2004-05-26 2008-06-04 ファイザー・インク 新規インダゾール及びインドロン誘導体及び調合剤としてのそれらの使用
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US20070129364A1 (en) * 2005-12-07 2007-06-07 Han-Qing Dong Pyrrolopyridine kinase inhibiting compounds
EA017852B1 (ru) 2006-12-20 2013-03-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные замещенных индазолов, активные в качестве ингибиторов киназ
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
BRPI0812450A2 (pt) 2007-06-05 2019-09-24 Schering Corp derivados de indazol policíclicos e seu uso como inibidores de erk para o tratamento de câncer
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
WO2009099982A1 (en) * 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors

Also Published As

Publication number Publication date
EA018149B1 (ru) 2013-05-30
CN102421769A (zh) 2012-04-18
HRP20130323T1 (en) 2013-05-31
KR101373910B1 (ko) 2014-03-12
AU2010246114B2 (en) 2012-12-06
DK2427449T3 (da) 2013-04-22
RS52795B (sr) 2013-10-31
AR078411A1 (es) 2011-11-09
SG175909A1 (en) 2011-12-29
CO6450624A2 (es) 2012-05-31
ME01462B (me) 2014-04-20
PL2427449T3 (pl) 2013-08-30
ES2408117T3 (es) 2013-06-18
CA2760535A1 (en) 2010-11-11
TW201105652A (en) 2011-02-16
CL2011002781A1 (es) 2012-05-25
US20100286209A1 (en) 2010-11-11
NZ595553A (en) 2013-05-31
EP2427449A1 (en) 2012-03-14
WO2010129509A1 (en) 2010-11-11
MA33244B1 (fr) 2012-05-02
CA2760535C (en) 2014-01-14
MY160390A (en) 2017-03-15
UA104756C2 (ru) 2014-03-11
PE20160124A1 (es) 2016-02-24
AU2010246114A1 (en) 2011-11-03
KR20120004511A (ko) 2012-01-12
PT2427449E (pt) 2013-05-06
JO2860B1 (en) 2015-03-15
JP2012526126A (ja) 2012-10-25
HK1163665A1 (en) 2012-09-14
EP2427449B1 (en) 2013-04-03
BRPI1013748A2 (pt) 2016-04-05
HN2011002809A (es) 2013-07-22
US8268869B2 (en) 2012-09-18
CR20110580A (es) 2012-01-06
PE20120812A1 (es) 2012-07-08
ECSP11011441A (es) 2011-12-30
CN102421769B (zh) 2014-04-02
JP5555314B2 (ja) 2014-07-23
TWI382982B (zh) 2013-01-21
MX2011011342A (es) 2011-11-18
IL216004A (en) 2014-01-30
IL216004A0 (en) 2012-01-31
SI2427449T1 (sl) 2013-05-31

Similar Documents

Publication Publication Date Title
EA201171367A1 (ru) Винилиндазолильные соединения
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA201400178A1 (ru) Лечение рака молочной железы
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
HUS1900007I1 (hu) Kiméra, antigénreceptor-módosított T-sejt alkalmazása rák kezelésére
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
MY184101A (en) Indoles
CL2012003385A1 (es) Tratamiento para la incontinencia.
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
EA201170521A1 (ru) Новые соединения
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
EA201490559A1 (ru) Композиция для лечения свища
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EA201290642A1 (ru) Соединения и способы
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
PH12015501088A1 (en) Dimeric compounds
EA201890598A3 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
EA201170700A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
PL2467140T3 (pl) Lapatynib do leczenia raka

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KG MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ TJ RU